Study title:
A phase 2, single-arm, multi-cohort, multi-center trial to determine the efficacy and safety of jcar017 in adult subjects with aggressive b-cell non-hodgkin lymphoma
Date receipt dossier:
24 avr 2018
EudraCT number:
2017-000106-38
Company / Sponsor:
Celgene
Phase:
II
Treated organism:
Humans
Indication category:
Cancer therapy
Disease:
B-cell non-hodgkin lymphoma
Therapeutic approach:
Immunotherapy
Genetic modification:
EGFRt en chimeric antigen receptor against CD19
Method of transfer of nucleic acid of interest:
Lentiviral vector
Administered biological material:
Autologous Tcells transduced with lentiviral vectors (JCAR017)
Route of administration:
Intravenous
Locations in Belgium:
UZ Gent
Type of procedure:
Contained use only
Current status:
Assessed